Australia's Lumos Diagnostics gains on advancing respiratory test sales

Lumos Diagnostics LDX.AX rises 3.9% to A$0.027; marks biggest intraday percentage gain since May 7

Medical equipment supplier says it received and shipped $126,000 purchase order for FebriDx from iMedical, Inc.

Adds order largest single purchase order since the test's launch; signals rise in U.S. customer adoption and continued market acceptance of FebriDx

FebriDx is a rapid point-of-care respiratory test, which, according to Lumos, delivers results in around 10 minutes from a fingerstick blood sample

LDX falls 25.7% this year, as of last close